Literature DB >> 8783466

The influence of high-energy shock waves on the development of metastases.

G O Oosterhof1, E B Cornel, G A Smits, F M Debruyne, J A Schalken.   

Abstract

The hypothesis that exposure of a solid tumor to high-energy shock waves (HESW) could lead to an increase of metastases was investigated in an animal model. The highly metastatic AT-6 Dunning R3327 rat prostate cancer subline was implanted in the hind limb of a Fisher-Copenhagen rat and was exposed to 6000 shock waves delivered by an experimental lithotripter, or sham-treated, as soon as the tumor had reached a volume of 175-225 mm3. The tumor-bearing leg was amputated 24 h later and the number of metastases was examined 12 weeks thereafter at autopsy. Metastases were seen in 82% of the animals exposed to HESW and in 25% of the sham-treated animals. There was no significant difference in weight of the lungs that contained metastases, between sham and treated animals. These results were confirmed in a second experiment. We conclude that the metastatic spread of tumors with a high metastatic potential may be enhanced by shock-wave exposure.

Entities:  

Mesh:

Year:  1996        PMID: 8783466     DOI: 10.1016/0301-5629(95)02051-9

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  11 in total

Review 1.  Section 8--clinical relevance. American Institute of Ultrasound in Medicine.

Authors: 
Journal:  J Ultrasound Med       Date:  2000-02       Impact factor: 2.153

Review 2.  Section 6--mechanical bioeffects in the presence of gas-carrier ultrasound contrast agents. American Institute of Ultrasound in Medicine.

Authors: 
Journal:  J Ultrasound Med       Date:  2000-02       Impact factor: 2.153

Review 3.  Section 7--discussion of the mechanical index and other exposure parameters. American Institute of Ultrasound in Medicine.

Authors: 
Journal:  J Ultrasound Med       Date:  2000-02       Impact factor: 2.153

Review 4.  Section 4--bioeffects in tissues with gas bodies. American Institute of Ultrasound in Medicine.

Authors: 
Journal:  J Ultrasound Med       Date:  2000-02       Impact factor: 2.153

Review 5.  Image-guided ultrasound phased arrays are a disruptive technology for non-invasive therapy.

Authors:  Kullervo Hynynen; Ryan M Jones
Journal:  Phys Med Biol       Date:  2016-08-05       Impact factor: 3.609

Review 6.  Focused ultrasound: tumour ablation and its potential to enhance immunological therapy to cancer.

Authors:  Giovanni Mauri; Luca Nicosia; Zhen Xu; Salvatore Di Pietro; Lorenzo Monfardini; Guido Bonomo; Gianluca Maria Varano; Francesco Prada; Paolo Della Vigna; Franco Orsi
Journal:  Br J Radiol       Date:  2018-01-17       Impact factor: 3.039

7.  Reduction of peak acoustic pressure and shaping of heated region by use of multifoci sonications in MR-guided high-intensity focused ultrasound mediated mild hyperthermia.

Authors:  Ari Partanen; Matti Tillander; Pavel S Yarmolenko; Bradford J Wood; Matthew R Dreher; Max O Kohler
Journal:  Med Phys       Date:  2013-01       Impact factor: 4.071

8.  Release of Cell-free MicroRNA Tumor Biomarkers into the Blood Circulation with Pulsed Focused Ultrasound: A Noninvasive, Anatomically Localized, Molecular Liquid Biopsy.

Authors:  John R Chevillet; Tatiana D Khokhlova; Maria D Giraldez; George R Schade; Frank Starr; Yak-Nam Wang; Emily N Gallichotte; Kai Wang; Joo Ha Hwang; Muneesh Tewari
Journal:  Radiology       Date:  2016-11-01       Impact factor: 11.105

9.  Evaluation of pulsed high intensity focused ultrasound exposures on metastasis in a murine model.

Authors:  Hilary Hancock; Matthew R Dreher; Nigel Crawford; Claire B Pollock; Jennifer Shih; Bradford J Wood; Kent Hunter; Victor Frenkel
Journal:  Clin Exp Metastasis       Date:  2009-06-11       Impact factor: 5.150

10.  Investigation of the Therapeutic Effect of Doxorubicin Combined With Focused Shockwave on Glioblastoma.

Authors:  Wei-Hao Liao; Ming-Yen Hsiao; Yi Kung; Abel Po-Hao Huang; Wen-Shiang Chen
Journal:  Front Oncol       Date:  2021-07-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.